Skip to content
You are now leaving https://www.ionispharma.com to visit

IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington’s Disease

IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington’s disease, in patients Roche plans to initiate a pivotal study of IONIS-HTT Rx (RG6042) CARLSBAD, Calif. , Aug. 2, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc.